1. Kim MK, Lee WY, Kang JH, et al. 2014 clinical practice guidelines for overweight and obesity in Korea. Endocrinol Metab (Seoul). 2014; 29:405–409.
Article
2. Zheng W, McLerran DF, Rolland B, et al. Association between body-mass index and risk of death in more than 1 million Asians. N Engl J Med. 2011; 364:719–729.
3. Eslick GD. Gastrointestinal symptoms and obesity: a metaanalysis. Obes Rev. 2012; 13:469–479.
Article
4. Dibaise JK, Foxx-Orenstein AE. Role of the gastroenterologist in managing obesity. Expert Rev Gastroenterol Hepatol. 2013; 7:439–451.
Article
5. Jung HS, Choi MG, Baeg MK, et al. Obesity is associated with increasing esophageal acid exposure in Korean patients with gastroesophageal reflux disease symptoms. J Neurogastroenterol Motil. 2013; 19:338–343.
Article
6. Behary J, Kumbhari V. Advances in the endoscopic management of obesity. Gastroenterol Res Pract. 2015; 2015:757821.
Article
7. Gaur S, Levy S, Mathus-Vliegen L, Chuttani R. Balancing risk and reward: a critical review of the intragastric balloon for weight loss. Gastrointest Endosc. 2015; 81:1330–1336.
Article
8. Abu Dayyeh BK, Eaton LL, Woodman G, et al. A randomized, multicenter study to evaluate the safety and effectiveness of an intragastric balloon as an adjunct to a behavioral modification program in comparison with a behavioral modification program alone in the weight management of obese subjects. Gastrointest Endosc. 2015; 81:AB147.
9. Su HJ, Kao CH, Chen WC, Chang TT, Lin CY. Effect of intragastric balloon on gastric emptying time in humans for weight control. Clin Nucl Med. 2013; 38:863–868.
Article
10. Fogel R, De Fogel J, Bonilla Y, De La Fuente R. Clinical experience of transoral suturing for an endoluminal vertical gastroplasty:1-year follow-up in 64 patients. Gastrointest Endosc. 2008; 68:51–58.
11. Familiari P, Costamagna G, Bléro D, et al. Transoral gastroplasty for morbid obesity: a multicenter trial with a 1-year outcome. Gastrointest Endosc. 2011; 74:1248–1258.
Article
12. Foschi D, Corsi F, Lazzaroni M, et al. Treatment of morbid obesity by intraparietogastric administration of botulinum toxin: a randomized, double-blind, controlledstudy. Int J Obes (Lond). 2007; 31:707–712.
13. Topazian M, Camilleri M, Enders FT, et al. Gastric antral injections of botulinum toxin delay gastric emptying but do not reduce body weight. Clin Gastroenterol Hepatol. 2013; 11:145–150.e1.
Article
14. Lee SK. Current status of laparoscopic metabolic/bariatric surgery in Korea. J Minim Invasive Surg. 2015; 18:59–62.
Article
15. Keith JN. Endoscopic management of common bariatric surgical complications. Gastrointest Endosc Clin N Am. 2011; 21:275–285.
Article
16. Ellsmere JC, Thompson CC, Brugge WR, et al. Endoscopic interventions for weight loss surgery. Obesity (Silver Spring). 2009; 17:929–933.
Article
17. Patel JA, Patel NA, Piper GL, Smith DE 3rd, Malhotra G, Colella JJ. Perioperative management of cholelithiasis in patients presenting for laparoscopic Roux-en-Y gastric bypass: have we reached a consensus? Am Surg. 2009; 75:470–476.
Article
18. Wang AY, Sauer BG, Behm BW, et al. Single-balloon enteroscopy effectively enables diagnostic and therapeutic retrograde cholangiography in patients with surgically altered anatomy. Gastrointest Endosc. 2010; 71:641–649.
Article
19. Moreels TG, Hubens GJ, Ysebaert DK, Op de Beeck B, Pelckmans PA. Diagnostic and therapeutic double-balloon enteroscopy after small bowel Roux-en-Y reconstructive surgery. Digestion. 2009; 80:141–147.
Article